CEA-IL2v showed monotherapy efficacy and combination efficacy with an anti-PD-L1 antibody as well as antibody-dependent cellular cytotoxicity (ADCC)-competent antibodies in mouse tumor models. Here, CEACAM5 is linked to neoplasm.